Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Road Runner Research Ltd

Neither a doctor nor a teaching hospital

Research payments

$1,604,723

513 payments

Through program year 2025, Road Runner Research Ltd is reported as receiving $1,604,723 in research payments, across 513 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $133,708 52
2024 Research $123,506 40
2023 Research $209,671 57
2022 Research $142,785 51
2021 Research $218,955 82
2020 Research $344,132 75
2019 Research $431,967 156

Breakdown

Who paid Research payments · program years 2019–2025
  1. H. Lundbeck A S $322,526 148 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $304,668 10 payments
  3. AbbVie, Inc. $272,633 99 payments
  4. F. Hoffmann-La Roche AG $205,627 90 payments
  5. Neurocrine Biosciences, Inc. $121,884 50 payments
  6. AstraZeneca Pharmaceuticals LP $119,643 11 payments
  7. Hoffmann-La Roche Limited $101,054 49 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $24,680 7 payments
  9. Harmony Biosciences LLC $23,965 7 payments
  10. GlaxoSmithKline, LLC. $20,515 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. V1a 2 in Pediatric Autism $205,627 90 payments
  2. An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period $186,784 98 payments
  3. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $128,238 41 payments
  4. Study to Assess Scales for RRB in Asd Non Drug Study Digital Biomarker $101,395 52 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $87,437 12 payments
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $77,802 32 payments
  7. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $76,605 2 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder $70,770 2 payments
  9. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00013) $64,093 1 payment
  10. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Nbi-98854 in Pediatric Subjects With Tourette Syndrome $56,330 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record